Skip to main content

Table 5 Univariable survival analysis of immune metagenes stratified by subtype and proliferation tertile.

From: Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis

Subtype PL PI PH
  HR (95%CI) P -value2 HR (95%CI) P -value HR (95%CI) P -value
ER- n = 51 3 n = 101 n = 249
B/P (L, I, H)1: 0.81 (0.33 to 2.00) 0.65 0.60 (0.41 to 0.89) 0.01 0.63 (0.48 to 0.83) 0.001
T/NK (L, I, H): 3.67 (1.13 to 11.9) 0.01 0.54 (0.38 to 0.78) 0.001 0.59 (0.44 to 0.78) 0.0003
M/D (L, I, H): 3.90 (1.28 to 11.9) 0.003 0.65 (0.45 to 0.94) 0.02 0.59 (0.45 to 0.78) 0.0002
ER+ n = 542 n = 458 n = 343
B/P (L, I, H): 0.77 (0.56 to 1.04) 0.09 1.03 (0.81 to 1.30) 0.83 0.56 (0.45 to 0.69) < 0.0001
T/NK (L, I, H): 0.80 (0.59 to 1.10) 0.17 0.98 (0.78 to 1.23) 0.85 0.60 (0.48 to 0.73) < 0.0001
M/D (L, I, H): 0.86 (0.64 to 1.16) 0.33 0.93 (0.74 to 1.18) 0.57 0.59 (0.48 to 0.73) < 0.0001
Basal-like n = 40 n = 113 n = 307
B/P (L, I, H): 0.97 (0.47 to 2.02) 0.94 0.64 (0.43 to 0.96) 0.03 0.67 (0.52 to 0.85) 0.001
T/NK (L, I, H): 1.63 (0.68 to 3.95) 0.23 0.48 (0.33 to 0.69) 0.0002 0.65 (0.51 to 0.83) 0.0006
M/D (L, I, H): 1.87 (0.74 to 4.72) 0.14 0.54 (0.37 to 0.79) 0.002 0.60 (0.47 to 0.77) < 0.0001
HER2-E n = 14 n = 66 n = 94
B/P (L, I, H): 0.70 (0.17 to 2.85) 0.62 0.72 (0.46 to 1.14) 0.16 0.51 (0.34 to 0.78) 0.002
T/NK (L, I, H): 0.08 (0.007 to 0.9) 0.02 0.79 (0.53 to 1.16) 0.23 0.46 (0.31 to 0.68) 0.0001
M/D (L, I, H): 0.66 (0.24 to 1.85) 0.43 0.96 (0.64 to 1.46) 0.86 0.53 (0.36 to 0.78) 0.001
Luminal B n = 26 n = 135 n = 212
B/P (L, I, H): 2.28 (0.82 to 6.32) 0.11 0.97 (0.65 to 1.43) 0.86 0.52 (0.38 to 0.71) < 0.0001
T/NK (L, I, H): 2.81 (1.06 to 7.49) 0.03 0.68 (0.43 to 1.08) 0.09 0.60 (0.45 to 0.80) 0.0002
M/D (L, I, H): 2.23 (0.83 to 5.96) 0.11 0.50 (0.30 to 0.83) 0.003 0.57 (0.42 to 0.77) < 0.0001
Luminal A n = 347 n = 200 n = 20
B/P (L, I, H): 0.71 (0.44 to 1.13) 0.14 0.95 (0.58 to 1.56) 0.83 1.41 (0.52 to 3.86) 0.50
T/NK (L, I, H): 0.57 (0.33 to 0.97) 0.03 1.08 (0.68 to 1.72) 0.73 0.98 (0.34 to 2.79) 0.96
M/D (L, I, H): 0.70 (0.44 to 1.12) 0.13 1.10 (0.71 to 1.71) 0.66 1.45 (0.44 to 4.79) 0.55
Claudin-Low n = 31 n = 22 n = 39
B/P (L, I, H): 2.1 (0.53 to 8.00) 0.24 1.5 (0.59 to 3.79) 0.38 1.06 (0.56 to 2.03) 0.85
T/NK (L, I, H): > 100 (0.00 to +inf) 0.02 0.70 (0.28 to 1.74) 0.45 0.87 (0.44 to 1.73) 0.69
M/D (L, I, H): > 100 (0.00 to +inf) 0.05 0.63 (0.24 to 1.63) 0.36 0.78 (0.43 to 1.44) 0.44
  1. 1metagene tertiles (L: low; I: intermediate; H: high); 2likelihood ratio test P-value; 3number of cases in specified subtype and proliferation tertile. CI: confidence interval; ER: estrogen receptor-positive breast cancer; HER2-E: human epidermal growth factor receptor 2-enriched; HR: hazard ratio.